Compare RUN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | NAMS |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | 2015 | N/A |
| Metric | RUN | NAMS |
|---|---|---|
| Price | $13.44 | $34.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 8 |
| Target Price | $19.10 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 7.1M | 794.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.35 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $858,578,000.00 | N/A |
| Revenue This Year | $1.08 | $17.96 |
| Revenue Next Year | $4.42 | $540.65 |
| P/E Ratio | $7.79 | ★ N/A |
| Revenue Growth | ★ 12.97 | N/A |
| 52 Week Low | $5.38 | $14.92 |
| 52 Week High | $22.44 | $42.00 |
| Indicator | RUN | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 48.13 | 61.05 |
| Support Level | $12.01 | $34.05 |
| Resistance Level | $13.57 | $37.43 |
| Average True Range (ATR) | 0.72 | 1.69 |
| MACD | 0.27 | 0.58 |
| Stochastic Oscillator | 52.24 | 88.69 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.